Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
D000963:Antimetabolites / Q000378:metabolism / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects*; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D003980:Diazooxonorleucine / Q000378:metabolism / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005972:Glutaminase / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D007555:Isoxazoles / Q000378:metabolism / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D010080:Oxazoles / Q000627:therapeutic use*
D000963:Antimetabolites; D001391:Azo Compounds; D007555:Isoxazoles; D010080:Oxazoles; D003980:Diazooxonorleucine; D005973:Glutamine; D005972:Glutaminase; C006303:acivicin